Antiviral activities of MCC-478, a novel and specific inhibitor of hepatitis B virus

Antimicrobial Agents and Chemotherapy

Volumn 46, Issue 9, 2002, Pages 2872-2877

  Kamiya, Naohiro ^a   Kubota, Atsushi ^a   Iwase, Yumiko ^a   Sekiya, Kouichi ^a   Ubasawa, Masaru ^a   Yuasa, Satoshi ^a  

^a MITSUBISHI TANABE PHARMA CORPORATION   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO 6 (4 HYDROXYPHENYLTHIO) 9 [2 (PHOSPHONOMETHOXY)ETHYL]PURINE 2,2,2 TRIFLUOROETHYL ESTER; 2 AMINO 6 (4 METHOXYPHENYLTHIO) 9 [2 (PHOSPHONOMETHOXY)ETHYL]PURINE; 2 AMINO 6 (4 METHOXYPHENYLTHIO) 9 [2 (PHOSPHONOMETHOXY)ETHYL]PURINE 2,2,2 TRIFLUOROETHYL ESTER; 2 AMINO 6 (4 METHOXYPHENYLTHIO) 9 [2 (PHOSPHONOMETHOXY)ETHYL]PURINEBIS(2,2,2 TRIFLUOROETHYL) ESTER; ADEFOVIR; ALAMIFOVIR; ANTIVIRUS AGENT; LAMIVUDINE; MITOCHONDRIAL DNA; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIVIRAL ACTIVITY; ARTICLE; BIOAVAILABILITY; CONTROLLED STUDY; CYTOTOXICITY; DNA DETERMINATION; DRUG EFFICACY; DRUG SYNTHESIS; HEPATITIS B; HEPATITIS B VIRUS; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; VIRUS INHIBITION;

EID: 0036720277     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.46.9.2872-2877.2002     Document Type: Article

References (37)

1. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine
2. Sequence and organization of the human mitochondrial genome
3. Hepadnaviral assembly is initiated by polymerase binding to the encapsidation signal in the viral RNA genome
4. Transcripts and the putative RNA pregenome of duck hepatitis B virus: Implications for reverse transcription
5. Biochemical pharmacology of (+)- and (-)-2′,3′-dideoxy-3′-thiacytidine as anti-hepatitis B virus agents
6. Delayed cytotoxicity and selective loss of mitochondrial DNA in cells treated with the anti-human immunodeficiency virus compound 2′,3′-dideoxycytidine
7. (-)-2′-deoxy-3′-thiacytidine is a potent, highly selective inhibitor of human immunodeficiency virus type 1 and type 2 replication in vitro
8. Cellular and molecular events leading to mitochondrial toxicity of 1-(2-deoxy-2-fluoro-1-beta-D-arabinofuranosyl)-5-iodouracil in human liver cells
9. Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine and emitricitabine
10. Cross-resistance testing of antihepadnaviral compounds using novel recombinant baculoviruses which encode drug-resistant strains of hepatitis B virus
11. Lamivudine as initial treatment for chronic hepatitis B in the United States
12. Inhibition of the replication of hepatitis B virus in vitro by 2′,3′-dideoxy-3′-thiacytidine and related analogues
13. Clinical potential of emerging new agents in hepatitis B
14. The same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2′,3′-dideoxyinosine and 2′,3′-dideoxycytidine confers high-level resistance to the (-) enantiomer of 2′,3′-dideoxy-3′-thiacytidine
15. Synthesis of 9-(2-phosphonylmethoxyethyl) adenine and related compounds
16. Lamivudine: A review of its therapeutic potential in chronic hepatitis B
17. 9-(2-Phosphonomethoxyethyl) derivatives of purine nucleotide analogues: A comparison of their metabolism and interaction with cellular DNA synthesis
18. A one-year trial of lamivudine for chronic hepatitis B
19. Mitochondrial toxicity of antiviral drugs
20. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy
21. Adefovir dipivoxil
22. The polymerase L528M mutation cooperates with nucleotide-binding site mutations, increasing hepatitis B virus replication and drug resistance
23. Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds
24. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants
25. Transient selection of a hepatitis B virus polymerase gene mutant associated with a decreased replication capacity and famciclovir resistance
26. Lamivudine (3TC) resistance in HIV-1 reverse transcriptase involves steric hindrance with β-branched amino acids
27. Metabolism and in vitro antiretroviral activities of bis(pivaloyloxymethyl) prodrugs of acyclic nucleoside phosphonates
28. Mutations affecting hepadnavirus plus-strand DNA synthesis dissociate primer cleavage from translocation and reveal the origin of liver viral DNA
29. Synthesis, oral bioavailability determination and in vitro evaluation of prodrugs of the antiviral agent 9-[2-(phosphonomethoxy)ethyl]adenine (PMEA)
30. Replication of the genome of a hepatitis B-like virus by reverse transcription of an RNA intermediate
31. Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy
32. Stable expression and replication of hepatitis B virus genome in an integrated state in a human hepatoma cell line transfected with the cloned viral DNA
33. Formation of the pool of covalently closed circular viral DNA in hepadnavirus-infected cells
34. The reverse transcriptase of hepatitis B virus acts as a protein primer for viral DNA synthesis
35. Inhibitory effects of acyclic nucleoside phosphonate analogues on hepatitis B virus DNA synthesis in HB611 cells
36. Anti-hepatitis B virus activity and metabolism of 2′,3′-dideoxy-2′,3′-didehydro-β-L(-)-5 -fluorocytidine